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Abstract
Background: Oral squamous cell carcinoma (OSCC) constitutes 3 percent of all cancers with predominant oc-
currence in middle aged and elderly males. Tumour recurrence worsens disease prognosis and decreases quality 
of life in patients with OSCC. Proinflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis fac-
tor alpha (TNF-α) have been suggested to play a certain role in variety of tumours. The aim of this study was to 
investigate the relationship of pretreatment serum IL-6 and TNF-α levels on tumour recurrence in patients with 
OSCC in order to identify potential biomarkers for the early detection of disease recurrence. 
Material and Methods: The patients with newly diagnosed OSCC were treated and followed from the first visit 
from November 2006 until January 2008. Serum IL-6 and TNF-α concentrations were measured. The records of 
the patients were re-examined in July 2012 and data were recorded about cancer characteristics and tumour recur-
rence. Disease free survival was analyzed by Kaplan-Meier survival curves, log rank test and Cox proportional 
hazards regression. 
Results: Serum IL-6 was shown as an independent risk factor for tumour recurrence.  
Conclusions: Pretreatment serum IL-6 concentration may be a useful biomarker for identification of OSCC pa-
tients with increased risk of  the disease recurrence.
Key words: Serum IL-6, serum TNF-α, oral cancer, recurrence.
Skrinjar I, Brailo V, Vidovic-Juras D, Vucicevic-Boras V, Milenovic A. 
Evaluation of pretreatment serum interleukin-6 and tumor necrosis factor 
alpha as a potential biomarker for recurrence in patients with oral squamous 
cell carcinoma. Med Oral Patol Oral Cir Bucal. 2015 Jul 1;20 (4):e402-7.   
 http://www.medicinaoral.com/medoralfree01/v20i4/medoralv20i4p402.pdf
Article Number: 20373          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.20373
http://dx.doi.org/doi:10.4317/medoral.20373
Med Oral Patol Oral Cir Bucal. 2015 Jul 1;20 (4):e402-7.                                                                                                                                       Interleukin-6 and TNF-α for oral cancer recurrence
e403
Introduction
Oral squamous cell carcinoma (OSCC) accounts for 
95% of all oral cavity and oropharyngeal cancers (1). 
Despite the improvement in surgical and radiation 
therapy, 5-year survival rate has not significantly im-
proved. The stage of the tumour at the time of diagnosis 
is important predictor of survival. Tumour recurrence 
significantly worsens disease prognosis and decreases 
quality of life in patients with OSCC. 
It has been shown that inflammation plays a key role 
in different stages of carcinogenesis (2). Serum concen-
trations of cytokines can be attributed to the secretion 
from tumour cells as well to systemic immune response 
to the tumour growth (3).
Proinflammatory cytokines such as interleukin-6 
(IL-6) and tumour necrosis factor alpha (TNF-α) have 
been suggested to play a certain role in the variety of 
tumours. The increased levels of serum IL-6 in patients 
with head and neck squamous cell carcinoma (HNSCC) 
compared to the healthy controls have been found in 
previous reports (4-6). Serum IL-6 concentration might 
correlate with the stage of tumour proliferation in pa-
tients with HNSCC (7) and can be useful in the detec-
tion of metastases (8).
It has been shown that TNF-α could act as endogenous 
promotor of tumour via activation of NF-kB transcrip-
tional factor (9). Different tumour cells produce TNF-α, 
including ovarian cancer and breast cancer (2). Recent 
study has shown that high levels of plasma TNF-α and 
C-reactive protein affect survival in patients with HN-
SCC (10).  
The aim of this study was to investigate the correlation 
of serum IL-6 and TNF-α levels on tumour recurrence 
in patients with OSCC in order to identify potential bi-
omarkers for early detection of disease recurrence. 
Material and Methods
This was a prospective study of patients with newly di-
agnosed OSCC. The patients were treated and followed 
from the first visit (November 2006 - January 2008) 
until June 2012 at the Department of Maxillofacial Sur-
gery University Hospital Dubrava Zagreb, Croatia. The 
study included 36 patients (30 man and 6 women) with 
histologically confirmed OSCC, mean age 59 (range 
37-78) and 31 healthy volunteer blood donors (19 man 
and 12 women) with healthy oral mucosa, mean age 58 
(range 50-78). Cancer stage was determined by use of 
TNM classification according to American Joint Com-
mittee on Cancer. Exclusion criteria for OSCC patients 
was assigned diagnosis of autoimmune disease. 
Prior to the study, all the participants signed informed 
consent and the study was performed in accordance 
with the Declaration of Helsinki. The study was ap-
proved by the Ethics Committee of the School of Den-
tal Medicine University of Zagreb and financed by the 
Croatian Ministry of Science and Technology, project 
number 065-0650445-0485.
The recruitment of the patients began in November 2006 
when blood samples for IL-6 and TNF-α analysis were 
collected. Notations were made about age, sex, smoking 
status and cancer site. Cancer site was divided into ante-
rior and posterior regions of the mouth. Periodontal sta-
tus was determined by Community Periodontal Index of 
Treatment Needs (CPITN) (11). The records were again 
re-examined in July 2012 and data were recorded again 
about cancer stage, N classification, type of treatment 
and local recurrence, regional recurrence and/or meta-
static disease. The type of treatment was dichotomized 
as surgery with/without radiotherapy versus chemoradi-
otherapy. The patients were censored as having a recur-
rence or not at their last annual chart review. Time until 
recurrence was noticed as disease free survival. 
- Blood collection and cytokines analysis 
Blood samples were collected between 8 and 10 A.M. 
with standard method from the antecubital veins. In pa-
tients with OSCC blood was collected before any kind of 
treatment. Samples were stored at room temperature for 
90 minutes and then centrifuged for 10 minutes (ROTI-
NA 35, Hettich, Germany). Sera were separated with 
Pasteur pipette and frozen at -70°C until analyzed. 
Concentration of IL-6 and TNF-α were analyzed by 
chemiluminiscent enzyme-linked immune assay (ELI-
SA).
For each cytokine 300 µL of sera was put into vial and 
transferred into container with marbles on which pri-
mary antibodies (IMMULITE, Siemens, Germany) 
specific for certain cytokine were adsorbed. After in-
cubation and washing, secondary antibody labeled with 
enzyme (IMMULITE, Siemens, Germany) was added. 
After washing unbind secondary antibody, luminog-
enous substrate (adamantyl-1,2-dioxetane-phosphate) 
was added. Degradation of luminogenous substrate re-
sults in emission of light which is measured by lumi-
nometer.  Concentrations of cytokines were written by 
device in pg/ml. The lower limit of detection for IL-6 
was 2 pg/ml and for TNF-α 4 pg/ml. The highest limit 
of detection for both cytokines was 1000 pg/ml. If the 
concentrations were not detectable value of 0.001 pg/ml 
was recorded.
Elevated levels for each cytokine were defined as higher 
levels than the 95. percentile of a value in the control 
subjects (12).
- Statistical Analysis
Statistical analysis was performed by MedCalc 13.0.0. 
statistical programme (Ostend, Belgium). The Fisher 
exact test was used to compare cytokine concentra-
tions between groups. The Mann-Whitney U test and 
Kruskal-Wallis test were used to determine the associa-
tion of  concentration of IL-6 and TNF-α with control 
variables. 
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Disease free survival was analyzed by Kaplan-Meier 
survival curves, log rank test and Cox proportional haz-
ards regression. P-value <0.05 was considered signifi-
cant in all analyses.
Results
There were no significant differences regarding age and 
sex between the patients and the controls.
The elevated level of serum IL-6 was defined as >6 pg/ml 
and elevated level of serum TNF-α was defined as >28.6 
pg/ml according to previous study described earlier (12). 
The patients with OSCC had higher concentration of se-
rum IL-6 than the controls (Fisher exact test, p=0.006). 
No difference was found in the concentration of serum 
TNF-α between the patients and the controls (Table 
1). Table 2 shows clinical characteristic of the disease. 
Most of the patients had tumour stage 3 or stage 4, and 
only one patient had distant metastases in the time of 
the diagnosis.   
There were no differences between concentrations of 
serum IL-6 and TNF-α according to the age, cancer 
site, cancer stage and N classification (Table 3). It was 
shown that men have significantly higher serum IL-6 
and TNF-α levels when compared with the women 
(p=0.03; p=0.02 respectively) and that smokers have 
significantly higher serum TNF-α levels in comparison 
to the non-smokers (p=0.04).  Serum IL-6 concentra-
tions did not differ between smokers and non-smokers.
The results show that patients who had distant metastas-
es were younger (Fig. 1). Univariate analysis of tumour 
recurrence. Two-year recurrence rate was fourty-four 
percent. 
Univariate analysis by Kaplan-Meier survival curves 
and log rank test failed to show significance between 
serum IL-6 or TNF-α and disease free survival. Other 
factors including age, sex, smoking status, cancer site, 
cancer stage and N classification also did not correlate 
significantly with disease free survival. The treatment 
type was shown as an independent risk factor for re-
currence (Fig. 2). The patients who underwent surgery 
with/without radiotherapy had median disease free sur-
vival of 1080 days when compared to the patients who 
solely underwent chemoradiotherapy without surgery, 
and who had median disease free survival of 180 days. 
Multivariate analysis of tumour recurrence
All variables were analyzed by multivariate analysis to 
determine their significance when cofactors were con-
Serum IL-6 OSCC patients Controls 
<=6 pg/ml 28 31 
>6 pg/ml 8 0 
pa 0.006  
Serum TNF-Į    
<=28,6 pg/ml 36 30 
>28,6 pg/ml 0 1 
pa 0.463  
Table 1. Serum IL-6 and TNF-α in oral cancer pa-
tients and control subjects.
* Fisher exact test
N
Tumor localization 
Front parts of the 
oral cavity 11
Back parts of the 
oral cavity 21
Front and back parts 
of the oral cavity 4
Tumor size  
T1 4 
T2 8 
T3 12 
T4 12 
N classification*  
N0 17 
N1 5 
N2 12 
N3 1 
Distant metastases  Yes 1 No 35 
Tumor stage  
Stage 1 3 
Stage 2 6 
Stage 3 12 
Stage 4 15 
Table 2. Clinical characteristics of the disease.
* for one patient N classification is not known. N= 
number of patients.
Serum IL-6 
(median(range), 
pg/ml 
Serum TNF-Į 
(median(range), pg/ml 
Age
<59 years 
>59 years 
pa
2 (0.001-12) 
3 (0.001-14) 
0.236 
7 (4-17) 
7 (0.001-22) 
0.972 
Sex 
Male 
Female 
pa
3 (0.001-14) 
1 (0.001-2) 
0.03 
7 (0.001-22) 
5 (0.001-8) 
0.02 
Smokers
Non-smokers
pa
3 (0.001-14) 
1 (0.001-7) 
0.17 
7.5 (0.001-22) 
5 (0.001-10) 
0.04 
Cancer site 
Front regions 
Back regions 
Both regions 
pb
3 (0.001-12) 
2 (0.001-14) 
0.001 (0.001-4) 
0.206 
7 (4-10) 
6 (0.001-22) 
8 (6-13) 
0.641 
Cancer stage 
S1+S2 
S3+S4 
pa
3 (2-12) 
2 (0.001-14) 
0.202 
7 (4-11) 
7 (0.001-22) 
0.485 
N classification 
N0
N1+N2+N3
Pa
2 (0.001-14) 
2.5 (0.001-12) 
0.776 
5 (0.001-15) 
7 (7-22) 
0.288 
Table 3. Serum IL-6 and TNF-α and contol variables.
aMann-Whitney U test 
bKruskal-Wallis test
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trolled as was recommended in the previous study of 
Sun et al. (13).
For the purpose of multivariate analysis serum IL-6 and 
TNF-α was log transformed to eliminate the effect of 
extreme values. 
The results of multivariate Cox proportional hazards 
models for recurrence are shown in table 4. Serum IL-6, 
cancer site and type of therapy were significant risk fac-
tors for tumour recurrence. Higher pretreatment serum 
levels of IL-6 were significantly associated with disease 
recurrence (HR=1.57; 95% CI, 1.06-2.33, p=0.03). The 
patients with tumours located in the anterior and pos-
terior regions of the mouth had higher risk for recur-
rence (HR=10.59; 95% CI, 2.04.-55.06; p=0.005). The 
treatment type was also shown as independent factor 
of recurrence as was in univariate analysis (HR=24.83; 
95% CI, 4.18-147.40, p<0.001). Serum TNF-α, age, sex, 
smoking status, cancer stage and N classification were 
not significantly associated with the tumour recur-
rence. 
Fig. 1. Distant metastases according to age in patients with oral 
squamous cell carcinoma. The median age of patients with metasta-
ses was 53, the median age of patients without metastases was 61.
Fig. 2.  A Kaplan-Meier plot of treatment type.
Table 4. Cox proportional hazards regression models for recur-
rence events.
Significant variables Hazard ratio 95% CI p
Log serum IL-6 1.57 1.06-2.33 0.03 
Cancer site 
Both regions vs anterior and 
vs posterior regions  10.59 
2.04.-
55.06 0.005 
Type of therapy 
Surgery with/without 
radiotherapy vs 
chemoradiotherapy 
24.83 4.18-147.40 <0.001 
For IL-6 the hazard ratio is for a unit increase in log serum 
IL-6.
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Discussion
Our results have shown that pretreatment serum IL-6 
concentration may be a useful marker for identification 
of OSCC patients with increased risk for the disease 
recurrence. Early diagnosis of locoregional or meta-
static disease plays an important role in the prognosis 
of the patients with oral cancer (14-16). In this study, 
serum concentration of IL-6 was higher in oral cancer 
patients when compared to the controls which was also 
confirmed in other studies (4,6,8,17) Furthermore, the 
results of this study show that serum IL-6 was an inde-
pendent risk factor for the disease recurrence. 
Elevated serum IL-6 concentrations indicate that sys-
temic inflammatory response is involved in carcinogen-
esis. Tumour growth and invasion in the surrounding 
tissues induces inflammation while tumour necrosis 
and hypoxia may activate inflammatory response. 
Moreover, tumour cells themselves may increase pro-
duction of inflammatory cytokines such as IL-6 (18). 
Those cytokines react with immune and vascular sys-
tem and stimulate tumour cells growth, tumour inva-
sion and metastases (19). Some authors (10,20,21) did 
not report difference between serum IL-6 concentra-
tions in patients with OSCC and controls. In the sudy of 
Andersson et al. (10) patients with head and neck squa-
mous cell carcinoma were not age and sex matched with 
the healthy controls as it was in our study. The study of 
Vucicevic Boras et al. (21) had differences in age be-
tween control group (mean age 25) and patients with 
OSCC (mean age 55). The study of Czerninski et al. 
(20) included potentially premalignant disorders (oral 
dysplasia or oral lichen planus) and six healthy volun-
teers as a control against only healty volunteers in our 
study. Those differences in methodologies could explain 
different results. The results of this and other studies 
(5,7,22) indicate that serum IL-6 is elevated in OSCC 
patients and may be potential marker for tumour recur-
rence. The patients with elevated serum IL-6 concentra-
tion may benefit from more frequent recall visits for the 
purpose of early diagnosis of tumour recurrence. 
Although our results have shown that serum IL-6 con-
centration was higher in men than women, sex was not 
significant risk factor for tumour recurrence as was 
shown by other authors (14,22). Although sex did not 
have impact on tumour recurrence, both serum IL-6 and 
TNF-α were higher in men. Some authors have shown 
higher serum IL-6 and TNF-α levels in healthy smokers 
when compared to the healthy non-smokers and higher 
TNF-α levels in patients with periodontitis in compari-
son to the healthy controls (23). The results of this study 
have shown that men did not smoke significantly more 
than women (data not shown). There were no significant 
differences regarding CPITN between men and women, 
as well as no significant difference in CPITN between 
OSCC patients and healthy controls (data not shown). 
Therefore, we can exclude smoking and periodontal 
disease as a potential causes of differences between 
IL-6 and TNF-α serum concentration between men 
and women. Elevated levels of IL-6 and TNF-α in men 
compared to women could probably be explained by the 
fact that we had unequal sample size regarding men and 
women. This result has to be confirmed or rejected in 
the future study with approximate equal percent of both 
genders. 
Tumour recurrence was not dependent on the partici-
pants age which was also confirmed by others (14,24). 
Nevertheless, patients who had distant metastases were 
significantly younger which confirms the fact that oral 
cancer is more aggressive in younger people (25).
Cancer site was not associated with serum concentra-
tions of IL-6 and TNF-α. However cancer site was 
shown as a significant risk factor for tumour recurrence. 
Tumours located in the anterior and posterior regions of 
the oral cavity had worse prognosis in comparison to 
those located in the anterior or posterior regions only. 
There were four patients within this group and all of 
them had tumours which involved floor of the mouth 
and the base of the tongue. This finding indicates that 
tumours located in those regions are more aggressive 
which could be explained by different lymphatic drain-
age of the anterior and posterior regions of the mouth 
(26). Generally, lymph from the posterior regions drains 
to lower cervical lymph nodes and involvement of those 
nodes could be associated with poor prognosis in OSCC 
patients. 
The treatment type was shown as an independent risk 
factor for tumour recurrence. The patients who un-
derwent chemoradiotherapy only had worse prognosis 
in comparison to the patients who underwent surgery 
with/without radiotherapy. Cancer stage, on the other 
hand was not associated with tumour recurrence. Even 
though the treatment is based on the stage of the disease, 
different treatment modalities can be applied within the 
same stage based on factors like tumour site, capsule 
perforation, patient’s general state etc. Three patients 
treated with chemoraditherapy had tumours localized 
in the posterior regions of oral cavity which could have 
contributed to the outcome. Given the fact that there 
were only three patients in this group, this result should 
be taken with caution. 
Serum TNF-α concentration did not differ significantly 
between OSCC patients and healthy controls as was 
shown by other authors (6,27) and was not shown to be 
a significant risk factor for tumour recurrence. In this 
study, smokers had higher serum TNF-α concentrations 
in comparison to the non-smokers which indicates sys-
temic inflammatory response to the ingredients in ciga-
rette smoke as it was shown previously (23).  
In conclusion, pretreatment serum IL-6 concentration 
may be a useful biomarker for early detection of recur-
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rence in patients with OSCC. Patients with elevated pre-
treatment serum IL-6 levels should therefore be recalled 
more frequently.  
Further prospective studies involving greater number of 
OSCC patients are needed to confirm these findings.
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